AKT1 and breast cancer: Targeting mTORC1 alone with everolimus leads to consistent feedback activation of AKT while the dual mTORC1-2/PI3K inhibitor BEZ235 eliminates this feedback loop in breast cancer cells, yet both molecules are equally effective in inhibiting cell proliferation in vitro and in vivo despite these important signaling differences [38].